The crucial obesity data to watch for this year
This year has already started strong for obesity drug developers, with Novo Nordisk, Metsera and Hengrui/Kailera all proclaiming clinical successes for GLP-1-based drugs. What might the rest of 2025...
View ArticleTakeda discontinues US supply of gout drug Uloric
Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic versions, the company confirmed to Endpoints News. “We have taken this decision...
View ArticleUpcoming PDUFA dates may be ensnared by Trump's pause at HHS, analyst says
President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval decisions to later dates, a Raymond James analyst told investors on Thursday....
View ArticleMerck and Eisai reveal late-stage fail for Keytruda and Lenvima in...
The combination of Merck’s Keytruda and Eisai’s Lenvima failed to prolong patients’ lives versus the comparator in another cancer study, but the companies say they are committed to the approach. In the...
View ArticleWith Sam Altman’s help, Retro Biosciences eyes $1B to extend lifespan by 10...
Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed in a Friday email to Endpoints News. It would be one of the largest funding...
View ArticleBiogen paring back research efforts; Will Chinese biotechs threaten US...
Welcome to the weekend! We saw a flurry of health-related news from Washington DC this week as the Trump administration officially began its transition. Let’s go over it. On the day he was sworn into ...
View ArticleAgenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 data
Five months after the FDA blocked its plans for accelerated approval, Agenus is moving ahead with discussions with potential pharma partners to chart a more conventional registrational path for its...
View ArticleAllakos restructures after Phase 1 failure; AB2 inks deal with Nippon Shinyaku
Plus, news about GSK: Allakos reports Phase 1 failure, lays off 75% of staff: The biotech said AK006 did not produce a clinical benefit in patients with chronic spontaneous urticaria, a ...
View ArticleVeru's drug lessens loss of lean mass in patients taking Wegovy
Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors didn’t celebrate. The Miami biotech on Monday reported new Phase 2b data for ...
View ArticleTrump healthcare transition: Live updates, biotech, pharma news
It’s been one week since President Donald Trump returned to the Oval Office. We've already seen a flood of executive orders, and the pause on health agency communications has created a bit of a frenzy ...
View Article#ASCOGI25: Bristol Myers shares IO combo data in colorectal cancer; Pfizer...
Several drugmakers shared new clinical data at this year’s ASCO GI Symposium in San Francisco, and Endpoints News has rounded up a handful of notable presentations from Bristol Myers Squibb, Pfizer,...
View ArticleSage rejects Biogen’s deal offer, will look at other options
Sage Therapeutics knows it needs to do something. But it doesn't want to sell to its partner Biogen. On Monday, the troubled biotech said its board had unanimously rejected Biogen's ...
View ArticlePfizer inks $60M settlement to close Nurtec anti-kickback suit
Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its migraine medicine Nurtec ODT. A Pfizer spokesperson said the company has...
View ArticleObesity startup Found drives weight loss with low-cost generic drugs over...
Found, a telehealth startup that treats obesity with medication and lifestyle coaching, unveiled new research showing tens of thousands of its patients lost significant amounts of weight through its...
View ArticlePharmacy middlemen lose bid to toss new Hawaii complaint
The state of Hawaii can proceed with a lawsuit against the three largest pharmacy benefit managers after it updated its complaint, a federal judge has ruled. Judge Leslie Kobayashi of the US District...
View ArticleSarepta shares two-year DMD data that may inform Europe decision
Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene therapy Elevidys, showing that patients who received the gene therapy...
View ArticleUpdated: Cell therapy biotech Affini-T Therapeutics reduces staff
Affini-T Therapeutics laid off an undisclosed number of employees last week, CEO Jak Knowles confirmed in a post-publication email to Endpoints News on Tuesday. The startup was coming up on a likely...
View ArticleVersant's fourth obesity biotech starts with $65M and a GIP antagonist
Another obesity biotech emerged on Tuesday morning, this time taking a different approach to the GIP antagonism story than Amgen and another startup called Antag Therapeutics. Helicore Biopharma broke...
View ArticleITM aims to compete with Novartis after Phase 3 radiopharma win
ITM Isotope Technologies Munich plans to seek approval for its β-emitting radioligand in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following a Phase 3 success, the biotech said Tuesday....
View ArticleAtalanta gets $97M boost to take two siRNAs into clinic for rare neuro disorders
For five years, Atalanta Therapeutics operated with one investor. Now, F-Prime Capital is getting a bevy of financial support to propel two of the Boston biotech's RNAi drugs for rare neurological...
View Article